Mobile Menu Button
  • 14 Dec 15

Diffuse Cystic Lung Diseases: Definitive Diagnosis is Essential for Targeted Treatments

Diffuse cystic lung diseases (DCLDs) are uncommon and frequently misdiagnosed, in part because there are so many different causes. The most frequently encountered DCLDs in clinical practice are lymphangioleiomyomatosis (LAM), Birt-Hogg-Dubé syndrome (BHD), and pulmonary Langerhans cell histiocytosis (PLCH).1 But cystic lung disease can also be due to Light Chain Deposition Disease or a rare

Learn More →
  • 20 Aug 15

First FDA-Approved Treatment for LAM Spearheaded by UC Research

The Food and Drug Administration (FDA) recently approved the drug sirolimus for the treatment of lymphangioleiomyomatosis (LAM), a rare lung disorder primarily affecting women. The Multicenter International Lymphangioleiomyomatosis Efficacy and Safety of Sirolimus (MILES) trial, spearheaded by investigators at the University of Cincinnati Medical Center Division of Pulmonary, Critical Care & Sleep Medicine and Cincinnati

Learn More →
  • 09 Dec 14

Lymphangioleiomyomatosis Therapy Submitted for FDA Review

Lymphangioleiomyomatosis (LAM) is a rare, metastatic neoplasm in women that leads to cystic lung destruction and declining lung function. Until recently, LAM patients faced respiratory disability and the need for supplemental oxygen and lung transplantation without an effective therapy.

Learn More →
  • 18 Dec 15

Translational Pulmonary Science Center Uses Basic Science to Advance Diagnosis and Treatment of Rare Lung Diseases in Real Time

Understanding the pathogenesis, diagnosis, and treatment of lung disease requires the collaboration between basic and clinical scientists, and is the primary mission of the Translational Pulmonary Science Center (TPSC) at the University of Cincinnati Medical Center. Formed in 2013, the TPSC is a joint effort between the pulmonary divisions of Cincinnati Children’s Hospital Medical Center

Learn More →
  • 16 Sep 16

UC Researchers Play Key Roles at Rare Lung Diseases Research Conference

The 2016 International Rare Lung Diseases Research Conference is designed to educate patients, help jump-start clinical trials and offer a forum for the latest research on rare lung diseases, according to Frank McCormack, MD, Taylor Professor and Director of the Division of Pulmonary, Critical Care and Sleep Medicine. The conference is set for Sept. 22-25,

Learn More →
  • 12 Dec 14

US National Registry for Pulmonary Alveolar Proteinosis (PAP) Patients Critical to Success of Ongoing Research

Successful completion of the Multicenter International Lymphangioleiomyomatosis (LAM) Efficacy and Safety of Sirolimus (MILES) trial was critically dependent on communication and collaboration with the LAM patient community, which was made possible through their advocacy group, the LAM Foundation.

Learn More →